YPEL1 inhibitors are chemical compounds that specifically target and inhibit the activity of the YPEL1 (Yippee-like 1) protein, which is part of the highly conserved YPEL family of proteins. YPEL1 is known to be involved in various cellular processes, particularly those related to cell division, growth, and regulation of the cytoskeleton. The YPEL proteins share structural similarities, including the presence of conserved domains that suggest their involvement in intracellular signaling and cellular structure maintenance. YPEL1 is thought to play a role in coordinating cell cycle progression and mitotic spindle formation, both critical aspects of cellular division and proper cellular architecture. The inhibition of YPEL1 could lead to significant alterations in these processes, impacting how cells maintain their structure and how they move through the stages of division.
Inhibitors of YPEL1 work by binding to the protein, blocking its interaction with other molecular components or preventing it from executing its functions within the cell. This inhibition can affect several cellular pathways, particularly those linked to the regulation of mitosis and cellular morphology. By disrupting YPEL1 activity, these inhibitors may lead to changes in the dynamics of cytoskeletal organization, which is essential for maintaining cellular shape and integrity during division. Additionally, YPEL1's involvement in growth regulation means that its inhibition can influence the overall rate of cellular proliferation and the balance between growth and differentiation. Understanding the structural and functional characteristics of YPEL1 inhibitors is critical for identifying their specific binding mechanisms and the broader cellular impacts they may have, particularly regarding how they influence cellular architecture and division mechanics.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin, an mTOR inhibitor, may indirectly influence YPEL1 by affecting cell growth and proliferation pathways. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is an HDAC inhibitor that could indirectly affect YPEL1 by altering gene expression and chromatin structure. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $85.00 | 9 | |
Valproic Acid, another HDAC inhibitor, may indirectly affect YPEL1 through its impact on gene expression and histone modification. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine, a DNA methyltransferase inhibitor, could influence YPEL1 indirectly by affecting gene expression patterns. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, a PI3K inhibitor, might indirectly affect YPEL1 by modulating the PI3K/Akt signaling pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, another PI3K inhibitor, could have indirect effects on YPEL1 through alterations in PI3K/Akt signaling. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib, a proteasome inhibitor, might impact YPEL1 indirectly by affecting protein degradation pathways. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132, also a proteasome inhibitor, could influence YPEL1 indirectly by modulating the ubiquitin-proteasome system. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib, a kinase inhibitor, may indirectly affect YPEL1 through its broad targeting of cell signaling pathways. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib, a multi-targeted kinase inhibitor, might have indirect effects on YPEL1 by modulating various signaling pathways. |